查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年孤兒藥市場預測：按疾病類型、藥物類型、銷售、藥物、配銷通路和地區進行的全球分析
市場調查報告書
商品編碼
1383503

到 2030 年孤兒藥市場預測：按疾病類型、藥物類型、銷售、藥物、配銷通路和地區進行的全球分析

Orphan Drugs Market Forecasts to 2030 - Global Analysis By Disease Type, Drug Type, Sale, Drug, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球孤兒藥市場規模為 1,758 億美元，預計到 2030 年將達到 4,455 億美元，預測期內年複合成長率為 14.2%。

用於識別和治療罕見疾病的藥物稱為孤兒藥。孤兒藥物可以有效治療多種疾病，包括癌症、代謝性疾病、血液疾病、慢性疾病、進行性疾病、病毒性疾病和神經系統疾病。孤兒藥通常針對罕見疾病的特定遺傳或分子異常採取有針對性的方法。其結果是提供更準確和有效的治療方案，從而改善患者的治療結果，包括提高存活率、症狀控制和整體生活品質。

根據遺傳和罕見疾病（GARD）資訊中心的數據，美國已知的罕見疾病超過10,000種，影響著十分之一的人，美國有3000萬人。

提高對該病的認知

增加疾病知識是推動孤兒藥市場的一個主要因素，因為它提高了人們對罕見疾病的認知並推動了宣傳、資助和研究。此外，患者、醫療保健專業人員和倡導團體意識的提高增加了對有效治療方法的需求，並激勵製藥公司資助孤兒藥的研發。最終，我們將透過提供更容易獲得的專業治療方法來擴大市場並改善罕見疾病患者的生活。這還可以帶來財政支持、法規激勵和加強夥伴關係。

初期成本高

開發治療罕見疾病的藥物的過程需要廣泛的研究、臨床試驗和法規程序，成本高昂。此外，孤兒藥通常很昂貴，因為這些費用必須由藥品價格來支付。它們的高成本使得難以廣泛提供且價格合理的孤兒藥，並可能給保險公司、醫療保健系統和患者帶來挑戰。因此，患者的治療選擇有限，罕見疾病患者未滿足的醫療需求可能無法解決。

法規獎勵的演變

這些激勵措施包括擴大市場獨佔權、稅收優惠和更快的核准程序。這些激勵措施透過降低財務風險和縮短上市時間來激勵製藥公司投資孤兒藥開發。此外，此類激勵措施使這些項目在財務上更加可行，從而促進創新，讓更多人能夠滿足罕見疾病患者未滿足的醫療需求，孤兒藥變得可用。製藥公司和罕見疾病患者都可以從雙贏的局面中受益。因此，政府法規提供有利的獎勵，鼓勵罕見疾病治療方法的開發，是推動孤兒藥產業的主要因素。

與有限可能性相關的風險

有限的市場潛力可能會阻礙公司開拓孤兒藥市場，導致罕見疾病患者的治療選擇減少，並延遲獲得創新治療方法。此外，被稱為孤兒藥的藥物是為了治療僅影響少數人的罕見疾病而創建的。由於受影響的患者數量較少，這些藥物的市場規模比針對更常見疾病的藥物要小。此外，製藥公司可能會發現投資孤兒藥研發在經濟上並不可取，進而為市場擴張帶來障礙。

COVID-19 的影響

COVID-19 的爆發擾亂了世界各地醫療領域的工作流程。許多行業，包括一些與醫療保健相關的子行業，因這種疾病而被迫暫時關閉。孤兒藥市場也正在經歷負成長，包括篩檢服務減少、接觸專家的機會減少、治療中斷、大多數行業的業務限制、學術機構和研究缺乏資金以及許多問題在起作用，包括暫時關閉學術機構、供應鏈中斷以及提供所需服務和售後服務的困難。

預計腫瘤學領域在預測期內將是最大的。

腫瘤學領域估計佔最大佔有率。孤兒藥在腫瘤疾病的治療中扮演重要角色。專門用於治療僅影響少數患者的罕見疾病的藥物稱為孤兒藥。即使個別癌症類型不是罕見疾病，癌症類型中的某些亞型或突變也可能被歸類為罕見疾病。孤兒藥針對導致癌症發展和擴散的特定遺傳異常或分子途徑。有利的法規激勵措施、向精準醫療的轉變以及罕見癌症亞型盛行率的增加正在推動腫瘤孤兒藥物市場顯著成長。

生技藥品產業預計在預測期內年複合成長率最高

預計生技藥品領域將在預測期內出現良好的成長。對於患者數量較少的罕見疾病，可以開發生物製藥來針對導致疾病的潛在遺傳異常或分子途徑。這種集中的方法減少了可能的副作用並提高了治療效果。單株抗體是已開發的生物製藥之一。單株抗體特異性結合癌細胞上的某些蛋白質，導致免疫系統攻擊腫瘤。孤兒藥市場正在開發和核准用於治療罕見疾病（包括罕見癌症）的生物製藥越來越多。

比最大的地區

由於工業基礎設施的成長、可支配所得的增加以及有利的政府政策，亞太地區在預測期內佔據了最大的市場佔有率。此外，亞太地區的臨床試驗成長預計將快於美國和歐洲，有助於該地區的市場擴張。此外，政府配合措施擴大腫瘤中心和社區健康中心的數量預計將擴大開發中國家孤兒藥的供應。

複合年複合成長率最高的地區：

由於主要市場參與者和大量罕見疾病患者的存在，預計北美在預測期內將實現盈利成長。此外，孤兒藥核准數量的增加、處於市場開拓階段的孤兒藥數量的增加以及該地區孤兒藥支出的增加是推動北美地區孤兒藥市場的其他因素。一個促成因素。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球孤兒藥市場：依疾病類型

  • 腫瘤性疾病
    • 胰臟癌
    • 急性骨髓性白血病
    • 多發性骨髓瘤
    • 卵巢癌
    • 腎臟細胞癌
  • 代謝性疾病
    • 獵人症候群
    • 高雪氏症
    • 法布瑞氏症
    • 甲狀旁腺功能低下症
  • 血液和免疫疾病
    • 血友病
    • 遺傳性血管性水腫
  • 感染疾病
  • 神經系統疾病
    • 亨丁頓舞蹈症
    • 阿茲海默症

第6章 全球孤兒藥市場：依藥物類型

  • 非生技藥品
  • 生技藥品

第7章 全球孤兒藥市場：依銷售額分類

  • 處方
  • 通用的

第8章 全球孤兒藥市場：依藥物分類

  • 立樹山
  • Revlimid
  • 伊布維察
  • 奧狄沃
  • 達札雷克斯
  • 波馬主義者
  • 其他藥品

第9章 全球孤兒藥市場：依配銷通路

  • 網路藥房
  • 醫院藥房
  • 零售藥房
  • 其他配銷通路

第10章 全球孤兒藥市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • Bayer AG
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Novo Nordisk A/S
  • Alexion Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • AstraZeneca
  • Celgene Corporation
  • Mylan
  • Biogen
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Shire Pharmaceutical
Product Code: SMRC24351

According to Stratistics MRC, the Global Orphan Drugs Market is accounted for $175.8 billion in 2023 and is expected to reach $445.5 billion by 2030 growing at a CAGR of 14.2% during the forecast period. Drugs used to identify and treat uncommon medical conditions are known as orphan drugs. Numerous oncological, metabolic, hematologic, chronic, progressive, viral, and neurological illnesses can be effectively treated with them. Orphan medications often employ a targeted approach, concentrating on the particular genetic or molecular abnormalities that underlie a rare disease. This results in more precise and effective treatment options, leading to improved patient outcomes, including increased survival rates, symptom management, and overall quality of life.

According to the Genetic and Rare Diseases (GARD) Information Center, there are more than 10,000 known rare diseases in the U.S. that affect about 1 in 10 people or 30 million people in the U.S.

Market Dynamics:

Driver:

Rise in disease awareness

Growing knowledge of diseases is a major factor driving the market for orphan medications since it makes rare diseases better recognized, which encourages advocacy, funding, and research. Moreover, an increase in patient, healthcare professional and advocacy group awareness drives up the need for efficient therapies, which in turn motivates pharmaceutical corporations to fund research and development of orphan drugs. In the end, it expands the market and enhances the lives of people with rare diseases by making specialized therapies more accessible. Therefore, it also results in increased support for funding, regulatory incentives, and partnerships.

Restraint:

High initial costs

The process of creating medications for uncommon diseases can be costly due to the extensive research, clinical trials, and regulatory procedures involved. Additionally, orphan medications are generally costly since these expenses must be covered by drug prices. It can be difficult to deliver rare disease therapies that are both widely available and reasonably priced due to the high expenses, which can also pose access challenges for insurers, healthcare systems, and patients. Hence, this can leave patients with limited treatment options and hinder progress in addressing the unmet medical needs of individuals with rare diseases.

Opportunity:

Developments in regulatory incentives

Extended market exclusivity, tax rebates, and accelerated approval procedures are all included in these incentives. They incentivize pharmaceutical companies to spend money on the development of orphan drugs by lowering financial risks and accelerating time to market. Furthermore, these kinds of incentives make these ventures more financially viable, which in turn encourage innovation and make more orphan medications available to meet the unmet medical requirements of people with rare diseases. Pharmaceutical businesses and those with rare illnesses benefit from this in a win-win scenario. Hence, government regulations that provide favourable incentives to encourage the development of therapies for rare diseases are a major factor driving the orphan drug industry.

Threat:

Risks associated with limited potential

The limited market potential can discourage companies from pursuing orphan drug development, resulting in fewer treatment options for patients with rare diseases and potential delays in accessing innovative therapies. Moreover, drugs known as orphans are created to treat uncommon conditions that only a tiny number of people have. The market for these medications is less than that of medications for more prevalent disorders because of the small number of patients. Furthermore, pharmaceutical corporations may find it financially undesirable to invest in the research and development of orphan medications as a result, which is a drawback of the market's expansion.

COVID-19 Impact

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. Numerous industries, including some healthcare-related sub-sectors, have been forced to temporarily close their doors due to the disease. The market for orphan drugs has also experienced negative growth, which can be linked to a number of issues, including a drop in screening services, a decrease in access to specialists, treatment interruptions, restricted operations in the majority of industries, insufficient funding for academic institutions and research, the temporary closure of significant academic institutions, supply chain disruptions, and difficulties delivering necessary or post-sales services.

The oncological diseases segment is expected to be the largest during the forecast period

The oncological diseases segment is estimated to hold the largest share. Orphan drugs play a crucial role in the treatment of oncological diseases. A medication created especially to treat uncommon diseases that only affect a small number of patients is known as an orphan drug. Certain subtypes or mutations within a cancer type can be classified as rare diseases, even though individual cancer types might not be. These orphan medications target particular genetic defects or molecular pathways that contribute to the development and spread of cancer. Due to favourable regulatory incentives, a shift towards precision medicine, and the rising prevalence of rare cancer subtypes, the market for orphan drugs for oncological diseases has experienced significant growth.

The biologics segment is expected to have the highest CAGR during the forecast period

The biologics segment is anticipated to have lucrative growth during the forecast period. Biologics can be created to target the underlying genetic abnormalities or molecular pathways that cause the disease in the case of orphan diseases, where the patient population is small. This focused approach lowers possible side effects and improves treatment efficacy. One sort of biologic that has been developed is the monoclonal antibody. It binds specifically to certain proteins on cancer cells, causing the immune system to attack the tumor. The orphan drug market has witnessed a growing number of biologic drugs being developed and approved for rare diseases, including rare forms of cancer.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to the growing infrastructure of industries, rising disposable incomes, and favourable government policies in the region. Furthermore, clinical trial growth in Asia-Pacific is anticipated to accelerate beyond that of the United States and Europe, contributing to the region's market expansion. Moreover, it is anticipated that an increase in government initiatives to expand the number of oncology and community health centers will broaden the availability of orphan medications in developing nations.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to the presence of major market players and a large population of patients with orphan diseases. Additionally, a growing number of orphan product approvals, a sizable number of orphan drugs in the development stage, and rising orphan drug spending in the area are the other factors driving the orphan drug market in the North American region.

Key players in the market

Some of the key players in the Orphan Drugs Market include: Bayer AG, Novartis AG, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Amgen Inc., Novo Nordisk A/S, Alexion Pharmaceuticals Inc., GlaxoSmithKline plc, AstraZeneca, Celgene Corporation, Mylan, Biogen, Merck KGaA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company and Shire Pharmaceutical.

Key Developments:

In March 2023, F. Hoffmann-La Roche Ltd: Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease.

In January 2022, Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.

Disease Types Covered:

  • Oncological Diseases
  • Metabolic Diseases
  • Hematologic & Immunologic Diseases
  • Infectious diseases
  • Neurological diseases

Drug Types Covered:

  • Non-Biologics
  • Biologics

Sales Covered:

  • Prescribed
  • Generics

Drugs Covered:

  • Rituxan
  • Revlimid
  • Imbruvica
  • Opdivo
  • Darzalex
  • Pomalyst
  • Other Drugs

Distribution Channels Covered:

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Orphan Drugs Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Oncological Diseases
    • 5.2.1 Pancreatic Cancer
    • 5.2.2 Acute Myeloid Leukemia
    • 5.2.3 Multiple Myeloma
    • 5.2.4 Ovarian Cancer
    • 5.2.5 Renal Cell Carcinoma
  • 5.3 Metabolic Diseases
    • 5.3.1 Hunter Syndrome
    • 5.3.2 Gaucher Disease
    • 5.3.3 Fabry Disease
    • 5.3.4 Hypoparathyroidism
  • 5.4 Hematologic & Immunologic Diseases
    • 5.4.1 Hemophilia
    • 5.4.2 Hereditary Angioedema
  • 5.5 Infectious diseases
  • 5.6 Neurological diseases
    • 5.6.1 Huntington's Disease
    • 5.6.2 Alzheimer's Disease

6 Global Orphan Drugs Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Non-Biologics
  • 6.3 Biologics

7 Global Orphan Drugs Market, By Sale

  • 7.1 Introduction
  • 7.2 Prescribed
  • 7.3 Generics

8 Global Orphan Drugs Market, By Drug

  • 8.1 Introduction
  • 8.2 Rituxan
  • 8.3 Revlimid
  • 8.4 Imbruvica
  • 8.5 Opdivo
  • 8.6 Darzalex
  • 8.7 Pomalyst
  • 8.8 Other Drugs

9 Global Orphan Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Online Pharmacies
  • 9.3 Hospital Pharmacies
  • 9.4 Retail Pharmacies
  • 9.5 Other Distribution Channels

10 Global Orphan Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Bayer AG
  • 12.2 Novartis AG
  • 12.3 F. Hoffmann-La Roche Ltd
  • 12.4 Bristol-Myers Squibb Company
  • 12.5 Amgen Inc.
  • 12.6 Novo Nordisk A/S
  • 12.7 Alexion Pharmaceuticals Inc.
  • 12.8 GlaxoSmithKline plc
  • 12.9 AstraZeneca
  • 12.10 Celgene Corporation
  • 12.11 Mylan
  • 12.12 Biogen
  • 12.13 Merck KGaA
  • 12.14 Takeda Pharmaceutical Company Limited
  • 12.15 Eli Lilly and Company
  • 12.16 Shire Pharmaceutical

List of Tables

  • Table 1 Global Orphan Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Orphan Drugs Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Orphan Drugs Market Outlook, By Oncological Diseases (2021-2030) ($MN)
  • Table 4 Global Orphan Drugs Market Outlook, By Pancreatic Cancer (2021-2030) ($MN)
  • Table 5 Global Orphan Drugs Market Outlook, By Acute Myeloid Leukemia (2021-2030) ($MN)
  • Table 6 Global Orphan Drugs Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 7 Global Orphan Drugs Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 8 Global Orphan Drugs Market Outlook, By Renal Cell Carcinoma (2021-2030) ($MN)
  • Table 9 Global Orphan Drugs Market Outlook, By Metabolic Diseases (2021-2030) ($MN)
  • Table 10 Global Orphan Drugs Market Outlook, By Hunter Syndrome (2021-2030) ($MN)
  • Table 11 Global Orphan Drugs Market Outlook, By Gaucher Disease (2021-2030) ($MN)
  • Table 12 Global Orphan Drugs Market Outlook, By Fabry Disease (2021-2030) ($MN)
  • Table 13 Global Orphan Drugs Market Outlook, By Hypoparathyroidism (2021-2030) ($MN)
  • Table 14 Global Orphan Drugs Market Outlook, By Hematologic & Immunologic Diseases (2021-2030) ($MN)
  • Table 15 Global Orphan Drugs Market Outlook, By Hemophilia (2021-2030) ($MN)
  • Table 16 Global Orphan Drugs Market Outlook, By Hereditary Angioedema (2021-2030) ($MN)
  • Table 17 Global Orphan Drugs Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 18 Global Orphan Drugs Market Outlook, By Neurological diseases (2021-2030) ($MN)
  • Table 19 Global Orphan Drugs Market Outlook, By Huntington's Disease (2021-2030) ($MN)
  • Table 20 Global Orphan Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 21 Global Orphan Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 22 Global Orphan Drugs Market Outlook, By Non-Biologics (2021-2030) ($MN)
  • Table 23 Global Orphan Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 24 Global Orphan Drugs Market Outlook, By Sale (2021-2030) ($MN)
  • Table 25 Global Orphan Drugs Market Outlook, By Prescribed (2021-2030) ($MN)
  • Table 26 Global Orphan Drugs Market Outlook, By Generics (2021-2030) ($MN)
  • Table 27 Global Orphan Drugs Market Outlook, By Drug (2021-2030) ($MN)
  • Table 28 Global Orphan Drugs Market Outlook, By Rituxan (2021-2030) ($MN)
  • Table 29 Global Orphan Drugs Market Outlook, By Revlimid (2021-2030) ($MN)
  • Table 30 Global Orphan Drugs Market Outlook, By Imbruvica (2021-2030) ($MN)
  • Table 31 Global Orphan Drugs Market Outlook, By Opdivo (2021-2030) ($MN)
  • Table 32 Global Orphan Drugs Market Outlook, By Darzalex (2021-2030) ($MN)
  • Table 33 Global Orphan Drugs Market Outlook, By Pomalyst (2021-2030) ($MN)
  • Table 34 Global Orphan Drugs Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 35 Global Orphan Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 36 Global Orphan Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 37 Global Orphan Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 38 Global Orphan Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 39 Global Orphan Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.